The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).
 
Hope S. Rugo
Consulting or Advisory Role - Celltrion; Ionis Pharmaceuticals
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology
 
Antonio Llombart-Cussac
Stock and Other Ownership Interests - MedSIR
Consulting or Advisory Role - MedSIR
Patents, Royalties, Other Intellectual Property - MedSIR
 
Fabrice Andre
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Mark E. Robson
Honoraria - AstraZeneca
Consulting or Advisory Role - Change HealthCare
Research Funding - Abbvie (Inst); AstraZeneca (Inst); InVitae (Inst); Medivation (Inst); Myriad Genetics (Inst); Pfizer (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
Other Relationship - Clinical Care Options; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo; Merck; Pfizer
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Eisai; Lilly; Novartis; Taiho Pharmaceutical; Takeda
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Peter Schmid
Employment - Genentech (I); Roche (I)
Honoraria - AstraZeneca; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
David W. Cescon
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Agendia; AstraZeneca; Genomic Health; GlaxoSmithKline; Merck; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending - Biomarkers of TTK inhibitors (assigned to institution)
 
Jin Seok Ahn
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb-Ono Pharmaceutical; Eisai; Janssen; Menarini; MSD; Pfizer; Roche
Consulting or Advisory Role - Samsung Bioepis
 
Rita Nanda
Consulting or Advisory Role - Aduro Biotech; Athenex; Daiichi Sankyo; Genentech/Roche; ION Pharma; Macrogenics; Merck; Pfizer; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Other Relationship - G1 Therapeutics
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - bioTheranostics
 
Li Fan
Employment - Merck Sharp & Dohme
 
Jaime Alberto Mejia
Employment - Merck Sharp & Dohme
 
Vassiliki Karantza
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck